{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T05:20:13Z","timestamp":1775280013902,"version":"3.50.1"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"7791","license":[{"start":{"date-parts":[[2020,1,15]],"date-time":"2020-01-15T00:00:00Z","timestamp":1579046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2020,1,15]],"date-time":"2020-01-15T00:00:00Z","timestamp":1579046400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2020,1,23]]},"DOI":"10.1038\/s41586-019-1922-8","type":"journal-article","created":{"date-parts":[[2020,1,15]],"date-time":"2020-01-15T19:02:47Z","timestamp":1579114967000},"page":"549-555","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2236,"title":["B cells and tertiary lymphoid structures promote immunotherapy response"],"prefix":"10.1038","volume":"577","author":[{"given":"Beth A.","family":"Helmink","sequence":"first","affiliation":[]},{"given":"Sangeetha M.","family":"Reddy","sequence":"additional","affiliation":[]},{"given":"Jianjun","family":"Gao","sequence":"additional","affiliation":[]},{"given":"Shaojun","family":"Zhang","sequence":"additional","affiliation":[]},{"given":"Rafet","family":"Basar","sequence":"additional","affiliation":[]},{"given":"Rohit","family":"Thakur","sequence":"additional","affiliation":[]},{"given":"Keren","family":"Yizhak","sequence":"additional","affiliation":[]},{"given":"Moshe","family":"Sade-Feldman","sequence":"additional","affiliation":[]},{"given":"Jorge","family":"Blando","sequence":"additional","affiliation":[]},{"given":"Guangchun","family":"Han","sequence":"additional","affiliation":[]},{"given":"Vancheswaran","family":"Gopalakrishnan","sequence":"additional","affiliation":[]},{"given":"Yuanxin","family":"Xi","sequence":"additional","affiliation":[]},{"given":"Hao","family":"Zhao","sequence":"additional","affiliation":[]},{"given":"Rodabe N.","family":"Amaria","sequence":"additional","affiliation":[]},{"given":"Hussein A.","family":"Tawbi","sequence":"additional","affiliation":[]},{"given":"Alex P.","family":"Cogdill","sequence":"additional","affiliation":[]},{"given":"Wenbin","family":"Liu","sequence":"additional","affiliation":[]},{"given":"Valerie S.","family":"LeBleu","sequence":"additional","affiliation":[]},{"given":"Fernanda G.","family":"Kugeratski","sequence":"additional","affiliation":[]},{"given":"Sapna","family":"Patel","sequence":"additional","affiliation":[]},{"given":"Michael A.","family":"Davies","sequence":"additional","affiliation":[]},{"given":"Patrick","family":"Hwu","sequence":"additional","affiliation":[]},{"given":"Jeffrey E.","family":"Lee","sequence":"additional","affiliation":[]},{"given":"Jeffrey E.","family":"Gershenwald","sequence":"additional","affiliation":[]},{"given":"Anthony","family":"Lucci","sequence":"additional","affiliation":[]},{"given":"Reetakshi","family":"Arora","sequence":"additional","affiliation":[]},{"given":"Scott","family":"Woodman","sequence":"additional","affiliation":[]},{"given":"Emily Z.","family":"Keung","sequence":"additional","affiliation":[]},{"given":"Pierre-Olivier","family":"Gaudreau","sequence":"additional","affiliation":[]},{"given":"Alexandre","family":"Reuben","sequence":"additional","affiliation":[]},{"given":"Christine N.","family":"Spencer","sequence":"additional","affiliation":[]},{"given":"Elizabeth M.","family":"Burton","sequence":"additional","affiliation":[]},{"given":"Lauren E.","family":"Haydu","sequence":"additional","affiliation":[]},{"given":"Alexander J.","family":"Lazar","sequence":"additional","affiliation":[]},{"given":"Roberta","family":"Zapassodi","sequence":"additional","affiliation":[]},{"given":"Courtney W.","family":"Hudgens","sequence":"additional","affiliation":[]},{"given":"Deborah A.","family":"Ledesma","sequence":"additional","affiliation":[]},{"given":"SuFey","family":"Ong","sequence":"additional","affiliation":[]},{"given":"Michael","family":"Bailey","sequence":"additional","affiliation":[]},{"given":"Sarah","family":"Warren","sequence":"additional","affiliation":[]},{"given":"Disha","family":"Rao","sequence":"additional","affiliation":[]},{"given":"Oscar","family":"Krijgsman","sequence":"additional","affiliation":[]},{"given":"Elisa A.","family":"Rozeman","sequence":"additional","affiliation":[]},{"given":"Daniel","family":"Peeper","sequence":"additional","affiliation":[]},{"given":"Christian U.","family":"Blank","sequence":"additional","affiliation":[]},{"given":"Ton N.","family":"Schumacher","sequence":"additional","affiliation":[]},{"given":"Lisa H.","family":"Butterfield","sequence":"additional","affiliation":[]},{"given":"Monika A.","family":"Zelazowska","sequence":"additional","affiliation":[]},{"given":"Kevin M.","family":"McBride","sequence":"additional","affiliation":[]},{"given":"Raghu","family":"Kalluri","sequence":"additional","affiliation":[]},{"given":"James","family":"Allison","sequence":"additional","affiliation":[]},{"given":"Florent","family":"Petitprez","sequence":"additional","affiliation":[]},{"given":"Wolf Herman","family":"Fridman","sequence":"additional","affiliation":[]},{"given":"Catherine","family":"Saut\u00e8s-Fridman","sequence":"additional","affiliation":[]},{"given":"Nir","family":"Hacohen","sequence":"additional","affiliation":[]},{"given":"Katayoun","family":"Rezvani","sequence":"additional","affiliation":[]},{"given":"Padmanee","family":"Sharma","sequence":"additional","affiliation":[]},{"given":"Michael T.","family":"Tetzlaff","sequence":"additional","affiliation":[]},{"given":"Linghua","family":"Wang","sequence":"additional","affiliation":[]},{"given":"Jennifer A.","family":"Wargo","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2020,1,15]]},"reference":[{"key":"1922_CR1","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1158\/2159-8290.CD-15-1545","volume":"6","author":"PL Chen","year":"2016","unstructured":"Chen, P. L. et al. Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discov. 6, 827\u2013837 (2016).","journal-title":"Cancer Discov."},{"key":"1922_CR2","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","volume":"20","author":"JM Taube","year":"2014","unstructured":"Taube, J. M. et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin. Cancer Res. 20, 5064\u20135074 (2014).","journal-title":"Clin. Cancer Res."},{"key":"1922_CR3","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/PPO.0000000000000301","volume":"24","author":"TR Cottrell","year":"2018","unstructured":"Cottrell, T. R. & Taube, J. M. PD-L1 and emerging biomarkers in immune checkpoint blockade therapy. Cancer J. 24, 41\u201346 (2018).","journal-title":"Cancer J."},{"key":"1922_CR4","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1056\/NEJMc1713444","volume":"377","author":"M Yarchoan","year":"2017","unstructured":"Yarchoan, M., Hopkins, A. & Jaffee, E. M. Tumor mutational burden and response rate to PD-1 inhibition. N. Engl. J. Med. 377, 2500\u20132501 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1922_CR5","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers, M. et al. IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade. J. Clin. Invest. 127, 2930\u20132940 (2017).","journal-title":"J. Clin. Invest."},{"key":"1922_CR6","doi-asserted-by":"crossref","first-page":"11919","DOI":"10.1073\/pnas.1611421113","volume":"113","author":"SK Subudhi","year":"2016","unstructured":"Subudhi, S. K. et al. Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities. Proc. Natl Acad. Sci. USA 113, 11919\u201311924 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1922_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00608-2","volume":"8","author":"N Jacquelot","year":"2017","unstructured":"Jacquelot, N. et al. Predictors of responses to immune checkpoint blockade in advanced melanoma. Nat. Commun. 8, 592 (2017).","journal-title":"Nat. Commun."},{"key":"1922_CR8","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1126\/science.aan4236","volume":"359","author":"V Gopalakrishnan","year":"2018","unstructured":"Gopalakrishnan, V. et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359, 97\u2013103 (2018).","journal-title":"Science"},{"key":"1922_CR9","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1126\/science.aao3290","volume":"359","author":"V Matson","year":"2018","unstructured":"Matson, V. et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science 359, 104\u2013108 (2018).","journal-title":"Science"},{"key":"1922_CR10","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.aan3706","volume":"359","author":"B Routy","year":"2018","unstructured":"Routy, B. et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359, 91\u201397 (2018).","journal-title":"Science"},{"key":"1922_CR11","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/nrclinonc.2017.101","volume":"14","author":"WH Fridman","year":"2017","unstructured":"Fridman, W. H., Zitvogel, L., Saut\u00e8s-Fridman, C. & Kroemer, G. The immune contexture in cancer prognosis and treatment. Nat. Rev. Clin. Oncol. 14, 717\u2013734 (2017).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1922_CR12","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.3389\/fimmu.2017.01830","volume":"8","author":"EJ Colbeck","year":"2017","unstructured":"Colbeck, E. J., Ager, A., Gallimore, A. & Jones, G. W. Tertiary lymphoid structures in cancer: drivers of antitumor immunity, immunosuppression, or bystander sentinels in disease? Front. Immunol. 8, 1830 (2017).","journal-title":"Front. Immunol."},{"key":"1922_CR13","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.it.2014.09.006","volume":"35","author":"MC Dieu-Nosjean","year":"2014","unstructured":"Dieu-Nosjean, M. C., Goc, J., Giraldo, N. A., Saut\u00e8s-Fridman, C. & Fridman, W. H. Tertiary lymphoid structures in cancer and beyond. Trends Immunol. 35, 571\u2013580 (2014).","journal-title":"Trends Immunol."},{"key":"1922_CR14","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/cmi.2017.35","volume":"14","author":"A Sarvaria","year":"2017","unstructured":"Sarvaria, A., Madrigal, J. A. & Saudemont, A. B cell regulation in cancer and anti-tumor immunity. Cell. Mol. Immunol. 14, 662\u2013674 (2017).","journal-title":"Cell. Mol. Immunol."},{"key":"1922_CR15","doi-asserted-by":"crossref","first-page":"5597","DOI":"10.1158\/0008-5472.CAN-16-0431","volume":"76","author":"P Tsou","year":"2016","unstructured":"Tsou, P., Katayama, H., Ostrin, E. J. & Hanash, S. M. The emerging role of B cells in tumor immunity. Cancer Res. 76, 5597\u20135601 (2016).","journal-title":"Cancer Res."},{"key":"1922_CR16","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41568-019-0144-6","volume":"19","author":"C Saut\u00e8s-Fridman","year":"2019","unstructured":"Saut\u00e8s-Fridman, C., Petitprez, F., Calderaro, J. & Fridman, W. H. Tertiary lymphoid structures in the era of cancer immunotherapy. Nat. Rev. Cancer 19, 307\u2013325 (2019).","journal-title":"Nat. Rev. Cancer"},{"key":"1922_CR17","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1038\/s41591-018-0197-1","volume":"24","author":"RN Amaria","year":"2018","unstructured":"Amaria, R. N. et al. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat. Med. 24, 1649\u20131654 (2018).","journal-title":"Nat. Med."},{"key":"1922_CR18","volume":"17","author":"E Becht","year":"2016","unstructured":"Becht, E. et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 17, 218 (2016).","journal-title":"Genome Biol."},{"key":"1922_CR19","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.trecan.2016.10.010","volume":"2","author":"GJ Yuen","year":"2016","unstructured":"Yuen, G. J., Demissie, E. & Pillai, S. B lymphocytes and cancer: a love-hate relationship. Trends Cancer 2, 747\u2013757 (2016).","journal-title":"Trends Cancer"},{"key":"1922_CR20","doi-asserted-by":"crossref","first-page":"e1294296","DOI":"10.1080\/2162402X.2017.1294296","volume":"6","author":"G Chiaruttini","year":"2017","unstructured":"Chiaruttini, G. et al. B cells and the humoral response in melanoma: the overlooked players of the tumor microenvironment. OncoImmunology 6, e1294296 (2017).","journal-title":"OncoImmunology"},{"key":"1922_CR21","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1158\/0008-5472.CAN-11-3218","volume":"72","author":"G Erdag","year":"2012","unstructured":"Erdag, G. et al. Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. Cancer Res. 72, 1070\u20131080 (2012).","journal-title":"Cancer Res."},{"issue":"11","key":"1922_CR22","doi-asserted-by":"crossref","first-page":"djw144","DOI":"10.1093\/jnci\/djw144","volume":"108","author":"Michael D. Iglesia","year":"2016","unstructured":"Iglesia, M. D. et al. Genomic analysis of immune cell infiltrates across 11 tumor types. J. Natl. Cancer Inst. 108, (2016).","journal-title":"Journal of the National Cancer Institute"},{"key":"1922_CR23","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1007\/s00262-011-1071-x","volume":"60","author":"A Lad\u00e1nyi","year":"2011","unstructured":"Lad\u00e1nyi, A. et al. Prognostic impact of B-cell density in cutaneous melanoma. Cancer Immunol. Immunother. 60, 1729\u20131738 (2011).","journal-title":"Cancer Immunol. Immunother."},{"key":"1922_CR24","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.humpath.2016.03.022","volume":"54","author":"K Garg","year":"2016","unstructured":"Garg, K. et al. Tumor-associated B cells in cutaneous primary melanoma and improved clinical outcome. Hum. Pathol. 54, 157\u2013164 (2016).","journal-title":"Hum. Pathol."},{"key":"1922_CR25","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1007\/s00262-007-0286-3","volume":"56","author":"A Lad\u00e1nyi","year":"2007","unstructured":"Lad\u00e1nyi, A. et al. Density of DC-LAMP+ mature dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factor. Cancer Immunol. Immunother. 56, 1459\u20131469 (2007).","journal-title":"Cancer Immunol. Immunother."},{"key":"1922_CR26","doi-asserted-by":"crossref","first-page":"829","DOI":"10.4161\/onci.20492","volume":"1","author":"L Martinet","year":"2012","unstructured":"Martinet, L. et al. High endothelial venules (HEVs) in human melanoma lesions: Major gateways for tumor-infiltrating lymphocytes. OncoImmunology 1, 829\u2013839 (2012).","journal-title":"OncoImmunology"},{"key":"1922_CR27","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1111\/his.12235","volume":"63","author":"G Avram","year":"2013","unstructured":"Avram, G. et al. The density and type of MECA-79-positive high endothelial venules correlate with lymphocytic infiltration and tumour regression in primary cutaneous melanoma. Histopathology 63, 852\u2013861 (2013).","journal-title":"Histopathology"},{"key":"1922_CR28","doi-asserted-by":"crossref","DOI":"10.1038\/srep00765","volume":"2","author":"JL Messina","year":"2012","unstructured":"Messina, J. L. et al. 12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy? Sci. Rep. 2, 765 (2012).","journal-title":"Sci. Rep."},{"key":"1922_CR29","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1158\/0008-5472.CAN-13-1342","volume":"74","author":"J Goc","year":"2014","unstructured":"Goc, J. et al. Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells. Cancer Res. 74, 705\u2013715 (2014).","journal-title":"Cancer Res."},{"key":"1922_CR30","doi-asserted-by":"crossref","first-page":"e1378844","DOI":"10.1080\/2162402X.2017.1378844","volume":"7","author":"F Posch","year":"2017","unstructured":"Posch, F. et al. Maturation of tertiary lymphoid structures and recurrence of stage II and III colorectal cancer. OncoImmunology 7, e1378844 (2017).","journal-title":"OncoImmunology"},{"key":"1922_CR31","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1158\/0008-5472.CAN-17-1987","volume":"78","author":"K Sili\u0146a","year":"2018","unstructured":"Sili\u0146a, K. et al. Germinal centers determine the prognostic relevance of tertiary lymphoid structures and are impaired by corticosteroids in lung squamous cell carcinoma. Cancer Res. 78, 1308\u20131320 (2018).","journal-title":"Cancer Res."},{"key":"1922_CR32","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1158\/0008-5472.CAN-12-1377","volume":"72","author":"A Cipponi","year":"2012","unstructured":"Cipponi, A. et al. Neogenesis of lymphoid structures and antibody responses occur in human melanoma metastases. Cancer Res. 72, 3997\u20134007 (2012).","journal-title":"Cancer Res."},{"key":"1922_CR33","doi-asserted-by":"crossref","DOI":"10.1186\/s13073-019-0647-5","volume":"11","author":"SR Selitsky","year":"2019","unstructured":"Selitsky, S. R. et al. Prognostic value of B cells in cutaneous melanoma. Genome Med. 11, 36 (2019).","journal-title":"Genome Med."},{"key":"1922_CR34","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-12160-2","volume":"10","author":"J Griss","year":"2019","unstructured":"Griss, J. et al. B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma. Nat. Commun. 10, 4186 (2019).","journal-title":"Nat. Commun."},{"key":"1922_CR35","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1038\/s41591-018-0198-0","volume":"24","author":"CU Blank","year":"2018","unstructured":"Blank, C. U. et al. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nat. Med. 24, 1655\u20131661 (2018).","journal-title":"Nat. Med."},{"issue":"7791","key":"1922_CR36","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","volume":"577","author":"Rita Cabrita","year":"2020","unstructured":"Cabrita, R. L. et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature https:\/\/doi.org\/10.1038\/s41586-019-1914-8 (2020).","journal-title":"Nature"},{"issue":"7791","key":"1922_CR37","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s41586-019-1906-8","volume":"577","author":"Florent Petitprez","year":"2020","unstructured":"Petitprez, F. et al. B cells are associated with survival and immunotherapy response in sarcoma. Nature https:\/\/doi.org\/10.1038\/s41586-019-1906-8 (2020).","journal-title":"Nature"},{"key":"1922_CR38","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1470-2045(18)30015-9","volume":"19","author":"RN Amaria","year":"2018","unstructured":"Amaria, R. N. et al. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol. 19, 181\u2013193 (2018).","journal-title":"Lancet Oncol."},{"key":"1922_CR39","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1158\/2326-6066.CIR-18-0619","volume":"7","author":"SM Reddy","year":"2019","unstructured":"Reddy, S. M. et al. Poor response to neoadjuvant chemotherapy correlates with mast cell infiltration in inflammatory breast cancer. Cancer Immunol. Res. 7, 1025\u20131035 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"1922_CR40","doi-asserted-by":"crossref","first-page":"399","DOI":"10.4143\/crt.2016.215","volume":"49","author":"IH Song","year":"2017","unstructured":"Song, I. H. et al. Predictive value of tertiary lymphoid structures assessed by high endothelial venule counts in the neoadjuvant setting of triple-negative breast cancer. Cancer Res. Treat. 49, 399\u2013407 (2017).","journal-title":"Cancer Res. Treat."},{"key":"1922_CR41","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1164\/rccm.201309-1611OC","volume":"189","author":"C Germain","year":"2014","unstructured":"Germain, C. et al. Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer. Am. J. Respir. Crit. Care Med. 189, 832\u2013844 (2014).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"1922_CR42","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","volume":"161","author":"Cancer Genome Atlas Network","year":"2015","unstructured":"Cancer Genome Atlas Network. Genomic classification of cutaneous melanoma. Cell 161, 1681\u20131696 (2015).","journal-title":"Cell"},{"key":"1922_CR43","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/nature12222","volume":"499","author":"Cancer Genome Atlas Research Network","year":"2013","unstructured":"Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499, 43\u201349 (2013).","journal-title":"Nature"},{"key":"1922_CR44","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.cell.2018.10.038","volume":"175","author":"M Sade-Feldman","year":"2018","unstructured":"Sade-Feldman, M. et al. Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell 175, 998\u20131013 (2018).","journal-title":"Cell"},{"key":"1922_CR45","unstructured":"FastQC. https:\/\/www.bioinformatics.babraham.ac.uk\/projects\/fastqc\/."},{"key":"1922_CR46","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"1922_CR47","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1093\/bioinformatics\/bts196","volume":"28","author":"DS DeLuca","year":"2012","unstructured":"DeLuca, D. S. et al. RNA-SeQC: RNA-seq metrics for quality control and process optimization. Bioinformatics 28, 1530\u20131532 (2012).","journal-title":"Bioinformatics"},{"key":"1922_CR48","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/bioinformatics\/btu638","volume":"31","author":"S Anders","year":"2015","unstructured":"Anders, S., Pyl, P. T. & Huber, W. HTSeq\u2014a Python framework to work with high-throughput sequencing data. Bioinformatics 31, 166\u2013169 (2015).","journal-title":"Bioinformatics"},{"key":"1922_CR49","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).","journal-title":"Nucleic Acids Res."},{"key":"1922_CR50","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.12688\/f1000research.7035.1","volume":"4","author":"MI Love","year":"2015","unstructured":"Love, M. I., Anders, S., Kim, V. & Huber, W. RNA-Seq workflow: gene-level exploratory analysis and differential expression. F1000 Res. 4, 1070 (2015).","journal-title":"F1000 Res."},{"key":"1922_CR51","first-page":"146","volume":"3","author":"G Wu","year":"2014","unstructured":"Wu, G., Dawson, E., Duong, A., Haw, R. & Stein, L. ReactomeFIViz: a Cytoscape app for pathway and network-based data analysis. F1000 Res. 3, 146 (2014).","journal-title":"F1000 Res."},{"key":"1922_CR52","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/bioinformatics\/btq675","volume":"27","author":"ME Smoot","year":"2011","unstructured":"Smoot, M. E., Ono, K., Ruscheinski, J., Wang, P. L. & Ideker, T. Cytoscape 2.8: new features for data integration and network visualization. Bioinformatics 27, 431\u2013432 (2011).","journal-title":"Bioinformatics"},{"key":"1922_CR53","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1101\/gr.1239303","volume":"13","author":"P Shannon","year":"2003","unstructured":"Shannon, P. et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 13, 2498\u20132504 (2003).","journal-title":"Genome Res."},{"key":"1922_CR54","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.cell.2018.02.052","volume":"173","author":"J Liu","year":"2018","unstructured":"Liu, J. et al. An integrated TCGA Pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell 173, 400\u2013416 (2018).","journal-title":"Cell"},{"key":"1922_CR55","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0166-4328(01)00297-2","volume":"125","author":"Y Benjamini","year":"2001","unstructured":"Benjamini, Y., Drai, D., Elmer, G., Kafkafi, N. & Golani, I. Controlling the false discovery rate in behavior genetics research. Behav. Brain Res. 125, 279\u2013284 (2001).","journal-title":"Behav. Brain Res."},{"key":"1922_CR56","doi-asserted-by":"crossref","first-page":"969","DOI":"10.3390\/cancers6020969","volume":"6","author":"EM Pimenta","year":"2014","unstructured":"Pimenta, E. M. & Barnes, B. J. Role of tertiary lymphoid structures (TLS) in anti-tumor immunity: potential tumor-induced cytokines\/chemokines that regulate TLS formation in epithelial-derived cancers. Cancers (Basel) 6, 969\u2013997 (2014).","journal-title":"Cancers (Basel)"},{"key":"1922_CR57","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1038\/bjc.2015.145","volume":"112","author":"N Hiraoka","year":"2015","unstructured":"Hiraoka, N. et al. Intratumoral tertiary lymphoid organ is a favourable prognosticator in patients with pancreatic cancer. Br. J. Cancer 112, 1782\u20131790 (2015).","journal-title":"Br. J. Cancer"},{"key":"1922_CR58","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1172\/JCI71611","volume":"124","author":"NH Ruddle","year":"2014","unstructured":"Ruddle, N. H. Lymphatic vessels and tertiary lymphoid organs. J. Clin. Invest. 124, 953\u2013959 (2014).","journal-title":"J. Clin. Invest."},{"key":"1922_CR59","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/s41588-018-0339-x","volume":"51","author":"X Hu","year":"2019","unstructured":"Hu, X. et al. Landscape of B cell immunity and related immune evasion in human cancers. Nat. Genet. 51, 560\u2013567 (2019).","journal-title":"Nat. Genet."},{"key":"1922_CR60","doi-asserted-by":"crossref","DOI":"10.1186\/s12859-015-0613-1","volume":"16","author":"VI Nazarov","year":"2015","unstructured":"Nazarov, V. I. et al. tcR: an R package for T cell receptor repertoire advanced data analysis. BMC Bioinformatics 16, 175 (2015).","journal-title":"BMC Bioinformatics"},{"key":"1922_CR61","doi-asserted-by":"crossref","first-page":"eaah4573","DOI":"10.1126\/science.aah4573","volume":"356","author":"AC Villani","year":"2017","unstructured":"Villani, A. C. et al. Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors. Science 356, eaah4573 (2017).","journal-title":"Science"}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41586-019-1922-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-019-1922-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-019-1922-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T14:08:59Z","timestamp":1732802939000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41586-019-1922-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,15]]},"references-count":61,"journal-issue":{"issue":"7791","published-print":{"date-parts":[[2020,1,23]]}},"alternative-id":["1922"],"URL":"https:\/\/doi.org\/10.1038\/s41586-019-1922-8","relation":{},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,15]]},"assertion":[{"value":"5 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.A.W. is an inventor on a US patent application (PCT\/US17\/53.717) submitted by the University of Texas MD Anderson Cancer Center that covers methods to enhance immune checkpoint blockade responses by modulating the microbiome. J.A.W. reports compensation for speaker\u2019s bureau and honoraria from Imedex, Dava Oncology, Omniprex, Illumina, Gilead, PeerView, Physician Education Resource, MedImmune and Bristol-Myers Squibb. J.A.W. serves as a consultant\/advisory board member for Roche\/Genentech, Novartis, AstraZeneca, GlaxoSmithKline, Bristol-Myers Squibb, Merck, Biothera Pharmaceuticals and Microbiome DX. J.A.W. also receives research support from GlaxoSmithKline, Roche\/Genentech, Bristol-Myers Squibb, and Novartis. J.A.W., S.M.R. and B.A.H. are co-inventors on an unpublished patent application related to methods of targeting B cells to enhance response to immune checkpoint blockade. M.T.T. reports advisory board participation and speaker paid honorarium from Nanostring and Myriad Genetics. M.A.D. serves as a paid consultant for BMS, Novartis, and Roche\/Genentech. M.A.D. also reports to be a principal investigator of a research grant from Roche\/Genentech and an unpaid consultant to Nanostring. C.U.B. reports an advisory role in BMS, MSD, Roche, Novartis, GSK, AZ, Pfizer, GenMab and Pierre Fabre. C.U.B. receives research funding from BMS, Novartis and Nanostring. C.U.B. reports stock\u00a0ownership from Uniti Cars and Neon Therapeutics. N.H. is a founder, stockholder and SAB member of Neon Therapeutics. W.H.F. serves as a consultant for AstraZeneca, Ipsen, Adaptimmune, OxfordBiotherapeutics, and Catalym. W.H.F. reports participation in data transparency committee for Servier and data management committee for Novartis. O.K. receives grant support from BMS. J.E.G. is a contributor of UpToDate-melanoma staging and prognosis. J.E.G. reports to be an unpaid member of Melanoma Research Foundation and Melanoma Research Alliance. J.E.G. reports to be on advisory board of Merck. R.K. reports to be scientific founder, stockholder and consultant of Codiak Biosciences. A.J.L. reports consultancies and research support from BMS, Genentech\/Roche and MedImmune\/Astra-Zeneca. P.S. reports a patent licensed to Jounce Therapeutics. P.S. serves as a consultant for Constellation, Jounce Therapeutics, Neon, BioAtla, Pieris, Oncolytics, Forty-Seven, Polaris, Apricity, Marker, Codiak, ImaginAb, Hummingbird, Dragonfly, Lytix and Bristol-Myers Squibb (BMS). P.S. has ownership interests in Jounce Therapeutics, Neon, Constellation, Oncolytics, BioAtla, Forty-Seven, Apricity, Polaris, Marker, Codiak, ImaginAb, Hummingbird, Dragonfly and Lytix. L.H.B. reports to be on StemImmune\/Calidi Scientific and Medical Advisory, Scientific Advisory Board of BoardNextCure, Replimmune, Western Oncolytics, Torque Therapeutics Khloris, Pyxis, Cytomix. L.H.B. reports to be Chair of Food and Drug Administration Cellular, Tissues and Gene Therapies Advisory Committee. R.Z. reports a patent application related to work on GITR, PD1 and CTLA4. R.Z. is a consultant for Leap Therapeutics. P.H. is on advisory board for Dragonfly, GlaxoSmithKline, Immatics and Sanofi. S.W., S.O. and M.B. are employees and stockholders of NanoString Technologies. All other authors report no competing interests directly relevant to this work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}